CSIMarket
 


Astrazeneca Plc  (AZN)
Other Ticker:  
 


Astrazeneca Plc's ROI from its fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Astrazeneca Plc's ROI in the fourth quarter of 2023?
Astrazeneca Plc achieved a return on average invested assets (ROI) of 16.41 % in its fourth quarter of 2023, this is above AZN's average return on investment of 10.77%.
Astrazeneca Plcs investments during the 12 months ending in the fourth quarter of 2023 are valued at $36 billion

ROI has improved compared to 9.21% in the third quarter of 2023, due to net income growth.

Within the Healthcare sector 17 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2023 from 0 to 181.

Definition and Formula of Return on Investment


Return On Investment (Dec 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Investment Change 6.47 % 6.47 % 6.47 % 6.47 % -
Y / Y Net Income Change 81.02 % - - - 2763.48 %
Investment (TTM) in Millions 36,322 36,322 36,322 36,322 34,114
Return On Investment (TTM) 16.41 % 9.21 % 9.35 % 9.5 % 9.65 %
AZN's Overall Ranking # 181 # 0 # 0 # 1065 #
Seq. Investment Change 0 % 0 % 0 % 6.47 % 0 %
Seq. Net Income Change - - - - -
Net Income (TTM) in Millions 5,961 3,293 3,293 3,293 3,293




Return On Investment AZN's Ranking
Within: No.
Industry # 9
Sector # 18
Overall # 181

Return On Investment Statistics
High Average Low
24.72 %
10.77 %
0.35 %
(Dec 31 2020)   (Dec 31 2021)







Financial Statements
Astrazeneca Plc's IV. Quarter Investments $ 36,322 Millions AZN's Balance sheet
Astrazeneca Plc's IV. Quarter Income $ 5,961 Millions Quarterly AZN's Income Statement
AZN's Income by Division See AZN's Income by Division


AZN Annual Return On Investment (Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
(Dec 31 2020)
2020
(Dec 31 2017)
2017
Total Investments in Millions 36,322 34,114 33,081 12,720 106,071
Y / Y Investment Growth 6.47 % 3.12 % 160.07 % -88.01 % -
Net Income in Millions 5,961 3,293 115 3,144 2,868
Y / Y Net Income Growth 81.02 % 2763.48 % -96.34 % 9.62 % -
Annual Return On Investment 16.41 % 9.65 % 0.35 % 24.72 % 2.7 %


Annual Roi Comment
In the fiscal year 2023 ROI improved to 16.41 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AZN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Return On Investment for AZN's Competitors
Roi for Astrazeneca Plc's Suppliers
Return On Investment for AZN's Customers

Other Ratios
AZN's Roa AZN's Inventory Turnover Ratio AZN's Growth Rates AZN's Dividend Statistics
AZN's Profitability Ratios AZN's Asset Turnover Ratio AZN's Dividend Growth
AZN's Roe AZN's Valuation Ratios AZN's Financial Strength Ratios AZN's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2023, within Healthcare Sector ROI
Siga Technologies Inc  43.86 %
Idexx Laboratories Inc  40.73 %
Star Equity Holdings Inc   40.67 %
Mimedx Group Inc   38.97 %
Medpace Holdings Inc   37.64 %
Elite Pharmaceuticals Inc   36.55 %
Mettler toledo International Inc   34.44 %
National Research Corporation  34.07 %
Alpha Tau Medical Ltd   31.12 %
Semler Scientific Inc   30.60 %
Virios Therapeutics Inc   28.59 %
Johnson and Johnson  26.63 %
Earth Science Tech Inc   26.10 %
Lantheus Holdings Inc   25.80 %
Inmode Ltd   25.09 %
Corcept Therapeutics Inc  21.53 %
Escalon Medical Corp   20.64 %
Vertex Pharmaceuticals Inc  20.61 %
Chemed Corporation  20.26 %
Novartis Ag  20.19 %
Harmony Biosciences Holdings inc   19.75 %
Catalyst Pharmaceuticals Inc   19.15 %
Zoetis Inc   18.93 %
West Pharmaceutical Services Inc   18.65 %
Protalix Biotherapeutics inc   18.12 %
Edwards Lifesciences Corporation  17.49 %
Exelixis Inc   17.29 %
Halozyme Therapeutics Inc   16.81 %
Astrazeneca Plc  16.41 %
United Therapeutics Corporation  15.77 %


Date modified: 2024-02-21T14:16:37+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com